表紙
市場調查報告書

兒童疫苗的全球市場:2019年∼2023年

Global Pediatric Vaccine Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 317310
出版日期 內容資訊 英文 128 Pages
訂單完成後即時交付
價格
兒童疫苗的全球市場:2019年∼2023年 Global Pediatric Vaccine Market 2019-2023
出版日期: 2019年02月14日內容資訊: 英文 128 Pages
簡介

Technavio團隊的分析師闡述,中低所得國的疫苗接種認識的高漲,成為市場獲得動力的最新趨勢。

強力的後期開發平台和新藥認證成為市場主要推動因素之一,另一方面疫苗的開發,保管,及處理相關的課題成為妨礙市場成長的大要素之一。

本報告提供全球兒童用疫苗市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 報告的範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 開發平台分析

第5章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第6章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第7章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • 共軛疫苗等
  • 弱毒化活病毒疫苗
  • 類毒素疫苗
  • 不活化疫苗
  • 市場機會:各產品

第8章 客戶形勢

第9章 市場區隔:各類型

  • 一價疫苗
  • 多價疫苗

第10章 地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第11章 成長要素與課題

  • 市場成長要素
  • 市場課題

第12章 市場趨勢

第13章 業者情勢

  • 概要
  • 創造性破壞狀況

第14章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • CSL Limited
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi

第15章 附錄

  • 調查方法
  • 簡稱的清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR30870

About this market

The prevalence of infectious diseases is high in the pediatric population, as the immune system of children is not fully developed. Therefore, infectious diseases are a leading cause of mortality in this population segment. Factors such as rising population as well as environmental and a few genetic factors are contributing to the rapidly growing incidences of infectious diseases. For instance, increased exposure to environmental factors such as ultraviolet radiation is responsible for the suppression of cell-based immunity in children, which makes them susceptible to numerous infectious diseases. Likewise, the rapid increase in birth rates is also a contributing factor to the rise in the number of infectious diseases. The increase in fertility rates is subsequently increasing the risk of maternally acquired infections such as HIV infection. All these factors are contributing to the increase in the prevalence of infectious diseases, which is further driving the market growth. Technavio's analysts have predicted that the pediatric vaccine market will register a CAGR of over 7% by 2023.

Market Overview

Strong late-stage pipeline and new drug approvals

The market contains a significant number of monotherapy- and combination therapy-based vaccines that are currently under the late stages of development and are expected to get approved during the forecast period. These vaccines possess a strong therapeutic potential for the prevention of a large number of infectious diseases and allergies in children. The therapeutic potential of these vaccines can be demonstrated by the results of clinical trials.

Hurdles to optimal use of vaccines

Hurdles such as supply constraints, inadequate vaccine coverage, and lack of knowledge regarding the importance of immunization are restricting the optimal use of vaccines in both developing as well as developed countries. However, the lack of vaccination coverage is responsible for millions of deaths among the pediatric population.

For the detailed list of factors that will drive and challenge the growth of the pediatric vaccine market during the 2019-2023, view our report.

Competitive Landscape

The pediatric vaccine market appears to be moderately concentrated and with the presence of limited vendors. The increasing prevalence of infectious diseases in pediatric population will drive the market growth This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1. Preface
  • 2.2. Preface
  • 2.3. Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Conjugate vaccines and others - Market size and forecast 2018-2023
  • Live-attenuated vaccines - Market size and forecast 2018-2023
  • Toxoid vaccines - Market size and forecast 2018-2023
  • Inactivated vaccines - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

  • Monovalent vaccines
  • Multivalent vaccines

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • CSL Limited
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Global vaccine market
  • Exhibit 02: Segments of global vaccine market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pediatric vaccines in the pipeline
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Conjugate vaccines and others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Conjugate vaccines and others - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Sales of leading conjugate vaccines 2015-2017 ($ millions)
  • Exhibit 23: Live-attenuated vaccines - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Live-attenuated vaccines - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Sales of leading live-attenuated vaccines 2015-2017 ($ millions)
  • Exhibit 26: Toxoid vaccines - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Toxoid vaccines - Year-over-year growth 2019-2023 (%)
  • Exhibit 28: Inactivated vaccines - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: Inactivated vaccines - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Market opportunity by product
  • Exhibit 31: Customer landscape
  • Exhibit 32: Market share by geography 2018-2023 (%)
  • Exhibit 33: Geographic comparison
  • Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Incidence rates for malaria 2017 (reported by the World Bank)
  • Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 43: Key leading countries
  • Exhibit 44: Market opportunity
  • Exhibit 45: Immunization programs for children
  • Exhibit 46: Recently approved vaccines by the FDA
  • Exhibit 47: Impact of drivers and challenges
  • Exhibit 48: Vendor landscape
  • Exhibit 49: Landscape disruption
  • Exhibit 50: Vendors covered
  • Exhibit 51: Vendor classification
  • Exhibit 52: Market positioning of vendors
  • Exhibit 53: CSL Limited - Vendor overview
  • Exhibit 54: CSL Limited - Business segments
  • Exhibit 55: CSL Limited - Organizational developments
  • Exhibit 56: CSL Limited - Geographic focus
  • Exhibit 57: CSL Limited - Segment focus
  • Exhibit 58: CSL Limited - Key offerings
  • Exhibit 59: GlaxoSmithKline plc - Vendor overview
  • Exhibit 60: GlaxoSmithKline plc - Business segments
  • Exhibit 61: GlaxoSmithKline plc - Organizational developments
  • Exhibit 62: GlaxoSmithKline plc - Geographic focus
  • Exhibit 63: GlaxoSmithKline plc - Segment focus
  • Exhibit 64: GlaxoSmithKline plc - Key offerings
  • Exhibit 65: Merck & Co., Inc. - Vendor overview
  • Exhibit 66: Merck & Co., Inc. - Business segments
  • Exhibit 67: Merck & Co., Inc. - Organizational developments
  • Exhibit 68: Merck & Co., Inc. - Geographic focus
  • Exhibit 69: Merck & Co., Inc. - Segment focus
  • Exhibit 70: Merck & Co., Inc. - Key offerings
  • Exhibit 71: Pfizer Inc. - Vendor overview
  • Exhibit 72: Pfizer Inc. - Business segments
  • Exhibit 73: Pfizer Inc. - Organizational developments
  • Exhibit 74: Pfizer Inc. - Geographic focus
  • Exhibit 75: Pfizer Inc. - Segment focus
  • Exhibit 76: Pfizer Inc. - Key offerings
  • Exhibit 77: Sanofi - Vendor overview
  • Exhibit 78: Sanofi - Business segments
  • Exhibit 79: Sanofi - Organizational developments
  • Exhibit 80: Sanofi - Geographic focus
  • Exhibit 81: Sanofi - Segment focus
  • Exhibit 82: Sanofi - Key offerings
  • Exhibit 83: Validation techniques employed for market sizing